The forecast for the import of Erythromycin to India from 2024 to 2028 shows a steady increase, with values expected to rise from $182.64 million in 2024 to $198.79 million in 2028. Comparing the year-on-year growth, we anticipate approximately a 2.28% annual increase from 2024 to 2025, and similar growth rates in the subsequent years, maintaining this upward trend.
The compounded annual growth rate (CAGR) over this forecast period is estimated to be modest, reflecting consistent growth in import values. As of 2023, the import value for Erythromycin stood at approximately $178.5 million.
Future trends to watch include potential changes in global demand for antibiotics, shifts in trade policies affecting pharmaceutical imports, and any significant developments in the domestic production capabilities within India. These factors could significantly influence import dynamics post-2028.
